FDA Approved: NEURACEQ — Supplemental Application (Lantheus Biosciences Ltd.)

View source ↗

Summary

The FDA granted a supplemental approval for NEURACEQ (florbetaben F-18), a PET imaging agent. The approval expands its use for evaluating beta-amyloid neuritic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia

Drugs mentioned

• NEURACEQ (Florbetaben F 18)

Snippet

SUPPL AP for NEURACEQ (FLORBETABEN F 18)